Lipid Management in Chronic Kidney Disease: Systematic Review of PCSK9 Targeting

Area of Science:

• Nephrology
• Cardiology
• Pharmacology

Background:

• Cardiovascular disease (CVD) is the primary cause of mortality in chronic kidney disease (CKD) patients.
• CKD is recognized as a risk equivalent for coronary artery disease.
• Statins, while standard for CVD prevention, have limited and debated efficacy in CKD patients, necessitating novel therapeutic strategies.

Purpose of the Study:

• To review current lipid management limitations in CKD.
• To evaluate the efficacy of anti-PCSK9 monoclonal antibodies in CKD patients based on available trial data.
• To highlight the need for further research on PCSK9 inhibitors in CKD for cardiovascular event reduction.

Main Methods:

• Review of clinical trial data, specifically subgroup analyses of alirocumab and evolocumab in CKD patients.
• Analysis of case reports on PCSK9 inhibitor efficacy in conditions like nephrotic syndrome.
• Assessment of limitations in current statin therapy and patient compliance in CKD.

Main Results:

• Subgroup analyses (ODYSSEY COMBO I & II) showed alirocumab significantly reduced LDL-cholesterol compared to placebo and ezetimibe when added to statins.
• Case reports indicate PCSK9 inhibitors may be effective in nephrotic syndrome.
• Statins demonstrate limited lipid-lowering and event reduction in CKD, with high non-compliance rates.

Conclusions:

• Anti-PCSK9 monoclonal antibodies represent a potential therapeutic advancement for managing cardiovascular risk in CKD.
• Further dedicated trials are essential to ascertain the safety and efficacy of PCSK9 inhibitors on cardiovascular outcomes specifically within the CKD population.
• High lipoprotein(a) levels in CKD warrant investigation into PCSK9 inhibitors' role in reducing cardiovascular events.